Propanc Hit With Nasdaq Delisting Notice; November 2 Delisting Unless It Appeals by October 30

summarizeSummary

Propanc received a Nasdaq notice on October 23 that it fails the $1.00 minimum bid price rule and, having already reverse split within the past year, is not eligible for a compliance period — its shares are set to delist November 2, 2026 unless it appeals by October 30. The company says it will appeal and believes it has already cured the deficiency.

check_boxKey Events · Legal and Risk Events · PPCB

• Nasdaq Bid Price Deficiency Notice

  Nasdaq notified Propanc on October 23, 2026 that its closing bid price was below the $1.00 minimum for the 30 consecutive business days prior to October 21, 2026, violating Listing Rule 5550(a)(2).

• No Cure Period; Delisting Set for November 2

  Under Listing Rule 5810(c)(3)(A)(iv) the company is ineligible for the standard 180-day compliance period because it had already effected a reverse stock split in the prior one-year period, so its securities will be delisted from the Nasdaq Capital Market on November 2, 2026 absent an appeal.

• Appeal Deadline October 30

  Propanc must request a hearing before a Nasdaq panel by October 30, 2026 to stay the delisting; the company states it intends to appeal and believes it has cured the bid price deficiency, though no Nasdaq confirmation is disclosed.

• Capital Access at Risk

  The filing warns a delisting could reduce liquidity and market price, shrink the investor base, and limit the company's ability to use a registration statement to offer and sell freely tradable securities — against a backdrop that includes a previously disclosed going concern warning in the FY2026 10-K.

auto_awesomeAnalysis · PPCB · Life Sciences

Nasdaq told Propanc on October 23 that its stock has traded below the $1.00 minimum bid for 30 straight business days, and because the company already did a reverse split within the past year it gets no 180-day cure window — the shares come off the Nasdaq Capital Market on November 2, 2026 unless the company appeals by October 30. Propanc says it will appeal and believes it has already fixed the bid price problem, but that is management's assertion, not a Nasdaq determination. A delisting would cut liquidity, shrink the pool of buyers, and block the company from using registration statements to sell stock — a serious problem for a company that already carries a going concern warning and needs access to public capital. The appeal filing by October 30 is the immediate checkpoint; a panel decision follows.